Cytosorbents (CTSO: http://www.cytosorb.com/
) and Aethlon Medical (AEMD: http://www.aethlonmedical.com/products/hemopurifier.htm
), both publicly traded corporations, have built something similar,: an extracorporeal filter that fits into the standard dialysis machine you can find in any hospital. By filtering out "cytokines", which are produced during inflammatory processes, they hope to increase survivability by halting "cytokine storm," which is kind of a runaway feedback-loop which leads to organ failure, septic shock, and death. If it is proved to increase patient survivability, this technology is huge: sepsis is a leading cause of expense and mortality in the United States. If it works as is hoped, there are many lives that could be saved and trainloads of money to be made. This PDF from the company makes the investment case: http://www.cytosorbents.com/pdf/CTSO_Investor_Presentation_-_Feb_2015.pdf
Both companies are attempting to commercialize their technologies and gain approvals in various countries. Cytosorbents has been steadily gaining approvals in the EU and other places worldwide. CTSO hopes to initially crack the US market through a trial using their filter as a part of cardiac surgery. AEMD is pursuing an FDA trial with their filter.
The two-hundred-billion-dollar question is whether their devices will broadly improve patient outcomes: they obviously filter out bad stuff from blood, but the real question is whether that is broadly effective in critical care situations.
I'm not a shill for either company, but I have significant investment gains in both. I'm constantly trying to assess how defensible each company's patent portfolio is, and whether the tech will improve general patent outcomes as much is suggested by a number of preliminary studies. I'd be interested in hearing other informed perspectives, especially from people doing research in this area.